A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine

Completed · Phase 2 · Has a placebo group

Conditions studied: Chronic Migraine, Chronic Migraine, Headache, Chronic Migraine Without Aura, Aura Migraine

In brief

This is a phase 2, double-blind, randomized, multicenter, placebo-controlled, three arm parallel study to evaluate the efficacy and safety of two different dosages (30 IU daily and 60 IU daily) of TNX-1900 in patients with chronic migraine.

Key facts

Study ID
NCT05679908
Run by
Tonix Pharmaceuticals, Inc.
People needed
88
Starts
2022-12-06
Expected to finish
2023-10-23
Last updated by the study team
2025-02-25

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.